Free Trial

Arrowhead Pharmaceuticals (ARWR) 10K Form and Latest SEC Filings 2026

Arrowhead Pharmaceuticals logo
$79.14 +4.21 (+5.62%)
Closing price 05/6/2026 04:00 PM Eastern
Extended Trading
$78.71 -0.43 (-0.54%)
As of 05/6/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Arrowhead Pharmaceuticals SEC Filings & Recent Activity

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has submitted 424+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Arrowhead Pharmaceuticals's financial statements. The most recent filing was a Form SCHEDULE 13G submitted on May 6, 2026.

Form 4
ARROWHEAD PHARMACEUTICALS, INC. Reports Ownership Change on Apr. 24, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Arrowhead Pharmaceuticals Files Current Report on Mar. 20, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Arrowhead Pharmaceuticals Files Annual Report on Nov. 25, 2025

The 10-K contains Arrowhead Pharmaceuticals's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Arrowhead Pharmaceuticals SEC Filing History

Browse Arrowhead Pharmaceuticals' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/06/2026 10:00 AM
Arrowhead Pharmaceuticals (879407) Subject
FMR LLC (315066) Filed by
Form SCHEDULE 13G
04/29/2026 3:44 PM
Arrowhead Pharmaceuticals (879407) Subject
VANGUARD CAPITAL MANAGEMENT LLC (2100119) Filed by
Form SCHEDULE 13G
04/28/2026 3:05 PM
Arrowhead Pharmaceuticals (879407) Subject
VANGUARD PORTFOLIO MANAGEMENT LLC (2100121) Filed by
Form SCHEDULE 13G
04/24/2026 5:38 PM
Arrowhead Pharmaceuticals (879407) Issuer
Hamilton James C (1830755) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/24/2026 5:44 PM
Apel Daniel Joseph (2081169) Reporting
Arrowhead Pharmaceuticals (879407) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/23/2026 3:44 PM
Arrowhead Pharmaceuticals (879407) Subject
Hamilton James C (1830755) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/22/2026 4:16 PM
Apel Daniel Joseph (2081169) Reporting
Arrowhead Pharmaceuticals (879407) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/26/2026 2:43 PM
Arrowhead Pharmaceuticals (879407) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/20/2026 3:05 PM
Arrowhead Pharmaceuticals (879407) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/09/2026 6:00 PM
Arrowhead Pharmaceuticals (879407) Issuer
Hamilton James C (1830755) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 3:49 PM
Arrowhead Pharmaceuticals (879407) Subject
Hamilton James C (1830755) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/12/2026 4:00 PM
Arrowhead Pharmaceuticals (879407) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/08/2026 5:45 PM
Arrowhead Pharmaceuticals (879407) Issuer
O'Brien Patrick (1627183) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2026 5:45 PM
Apel Daniel Joseph (2081169) Reporting
Arrowhead Pharmaceuticals (879407) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2026 5:45 PM
Arrowhead Pharmaceuticals (879407) Issuer
Hamilton James C (1830755) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/08/2026 4:05 PM
Arrowhead Pharmaceuticals (879407) Filer
Form 305B2
01/07/2026 8:12 PM
Arrowhead Pharmaceuticals (879407) Subject
Form FWP
01/08/2026 5:12 AM
Arrowhead Pharmaceuticals (879407) Subject
Form FWP
01/06/2026 3:05 PM
Arrowhead Pharmaceuticals (879407) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/05/2026 8:50 PM
Arrowhead Pharmaceuticals (879407) Issuer
O'Brien Patrick (1627183) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 8:39 PM
Anzalone Christopher Richard (1423029) Reporting
Arrowhead Pharmaceuticals (879407) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 8:41 PM
Arrowhead Pharmaceuticals (879407) Issuer
Hamilton James C (1830755) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2026 7:06 PM
Arrowhead Pharmaceuticals (879407) Subject
Hamilton James C (1830755) Reporting
Form 144/A
01/05/2026 3:59 PM
Arrowhead Pharmaceuticals (879407) Subject
Hamilton James C (1830755) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/02/2026 3:04 PM
Anzalone Christopher Richard (1423029) Reporting
Arrowhead Pharmaceuticals (879407) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/30/2025 4:46 PM
Arrowhead Pharmaceuticals (879407) Issuer
Ferrari Mauro (1506045) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/30/2025 4:46 PM
Anzalone Christopher Richard (1423029) Reporting
Arrowhead Pharmaceuticals (879407) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2025 3:23 PM
Anzalone Christopher Richard (1423029) Reporting
Arrowhead Pharmaceuticals (879407) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/23/2025 5:01 PM
Arrowhead Pharmaceuticals (879407) Issuer
OLUKOTUN ADEOYE Y (1242615) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 5:01 PM
Anzalone Christopher Richard (1423029) Reporting
Arrowhead Pharmaceuticals (879407) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 5:01 PM
Arrowhead Pharmaceuticals (879407) Issuer
Vakiener Victoria (1826263) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 5:01 PM
Arrowhead Pharmaceuticals (879407) Issuer
Waddill William D. (1553338) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2025 5:56 PM
Anzalone Christopher Richard (1423029) Reporting
Arrowhead Pharmaceuticals (879407) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2025 3:08 PM
Anzalone Christopher Richard (1423029) Reporting
Arrowhead Pharmaceuticals (879407) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/19/2025 3:06 PM
Arrowhead Pharmaceuticals (879407) Subject
Vakiener Victoria (1826263) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/19/2025 3:07 PM
Arrowhead Pharmaceuticals (879407) Subject
OLUKOTUN ADEOYE Y (1242615) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/19/2025 3:07 PM
Arrowhead Pharmaceuticals (879407) Subject
Waddill William D. (1553338) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/18/2025 5:39 PM
Arrowhead Pharmaceuticals (879407) Issuer
OLUKOTUN ADEOYE Y (1242615) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2025 5:39 PM
Arrowhead Pharmaceuticals (879407) Issuer
INGRAM DOUGLAS S (1190644) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2025 5:40 PM
Arrowhead Pharmaceuticals (879407) Issuer
Vakiener Victoria (1826263) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2025 5:40 PM
Arrowhead Pharmaceuticals (879407) Issuer
PERRY MICHAEL S (1250379) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2025 5:40 PM
Arrowhead Pharmaceuticals (879407) Issuer
Lu Hongbo (1767584) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2025 5:40 PM
Arrowhead Pharmaceuticals (879407) Issuer
Ferrari Mauro (1506045) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/18/2025 5:35 PM
Arrowhead Pharmaceuticals (879407) Issuer
Waddill William D. (1553338) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/17/2025 4:11 PM
Anzalone Christopher Richard (1423029) Reporting
Arrowhead Pharmaceuticals (879407) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/16/2025 3:47 PM
Anzalone Christopher Richard (1423029) Reporting
Arrowhead Pharmaceuticals (879407) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/16/2025 12:14 PM
Anzalone Christopher Richard (1423029) Reporting
Arrowhead Pharmaceuticals (879407) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/15/2025 3:50 PM
Anzalone Christopher Richard (1423029) Reporting
Arrowhead Pharmaceuticals (879407) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/10/2025 8:54 PM
Arrowhead Pharmaceuticals (879407) Filer
Form S-3ASR
12/09/2025 5:04 PM
Arrowhead Pharmaceuticals (879407) Issuer
PERRY MICHAEL S (1250379) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2025 5:10 PM
Arrowhead Pharmaceuticals (879407) Issuer
Ferrari Mauro (1506045) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/28/2025 12:19 PM
Arrowhead Pharmaceuticals (879407) Subject
Ferrari Mauro (1506045) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/25/2025 3:10 PM
Arrowhead Pharmaceuticals (879407) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/25/2025 3:13 PM
Arrowhead Pharmaceuticals (879407) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
11/18/2025 1:49 PM
Arrowhead Pharmaceuticals (879407) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/10/2025 3:02 PM
Arrowhead Pharmaceuticals (879407) Filer
Form 10-K/A
10/03/2025 5:15 PM
Arrowhead Pharmaceuticals (879407) Issuer
Hamilton James C (1830755) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/01/2025 2:44 PM
Arrowhead Pharmaceuticals (879407) Subject
Hamilton James C (1830755) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/16/2025 5:06 PM
Arrowhead Pharmaceuticals (879407) Issuer
Hamilton James C (1830755) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/12/2025 3:33 PM
Arrowhead Pharmaceuticals (879407) Subject
Hamilton James C (1830755) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/11/2025 6:31 AM
Arrowhead Pharmaceuticals (879407) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/04/2025 4:37 PM
Arrowhead Pharmaceuticals (879407) Issuer
Hamilton James C (1830755) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/02/2025 4:12 PM
Arrowhead Pharmaceuticals (879407) Subject
Hamilton James C (1830755) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/15/2025 4:59 PM
Arrowhead Pharmaceuticals (879407) Issuer
Hamilton James C (1830755) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/15/2025 4:28 PM
Arrowhead Pharmaceuticals (879407) Subject
Sarepta Therapeutics, Inc. (873303) Filed by
Form SCHEDULE 13D/A
08/15/2025 2:42 PM
Arrowhead Pharmaceuticals (879407) Subject
Hamilton James C (1830755) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/14/2025 6:07 AM
Arrowhead Pharmaceuticals (879407) Subject
Avoro Capital Advisors LLC (1633313) Filed by
Form SCHEDULE 13G/A
08/13/2025 7:55 PM
Arrowhead Pharmaceuticals (879407) Subject
Sarepta Therapeutics, Inc. (873303) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/13/2025 4:57 PM
Arrowhead Pharmaceuticals (879407) Subject
Hamilton James C (1830755) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/12/2025 4:49 PM
Apel Daniel Joseph (2081169) Reporting
Arrowhead Pharmaceuticals (879407) Issuer
Form 3
Initial statement of beneficial ownership of securities  
08/11/2025 6:01 AM
Arrowhead Pharmaceuticals (879407) Subject
STATE STREET CORP (93751) Filed by
STATE STREET CORP (93751) Filed by
Form SCHEDULE 13G
07/29/2025 10:20 AM
Arrowhead Pharmaceuticals (879407) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
07/10/2025 3:30 PM
Arrowhead Pharmaceuticals (879407) Subject
Myszkowski Kenneth Allen (1486672) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/13/2025 9:26 AM
Arrowhead Pharmaceuticals (879407) Subject
STATE STREET CORP (93751) Filed by
STATE STREET CORP (93751) Filed by
Form SCHEDULE 13G
(Data available from 1/1/2016 forward)

Arrowhead Pharmaceuticals SEC Filings - Frequently Asked Questions

Arrowhead Pharmaceuticals (ARWR) has submitted 424+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Arrowhead Pharmaceuticals's fiscal year ends on September 30. The company typically files its 10-K annual report by the end of November, covering the prior fiscal year's financial results. Key financial data from these reports is available on Arrowhead Pharmaceuticals's financial statements page.

The most recent filing was a Form SCHEDULE 13G submitted on May 6, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:ARWR) was last updated on 5/7/2026 by MarketBeat.com Staff.
From Our Partners